Creative Medical Technology (CELZ)
Develops regenerative cell therapies for pain and diabetes alongside physician-use procedure kits.
Something off on this page? Send us feedback.
Sells disposable CaverStem and FemCelz physician kits while developing allogeneic and immune-cell therapies for lower-back pain and recent-onset diabetes. Its economics remain anchored in limited kit sales and equity-funded clinical development.
Develops regenerative-medicine therapies while retaining a small commercial business selling disposable CaverStem and FemCelz kits to physicians for autologous procedures. Kit revenue is recognized on delivery; CaverStem marketing was paused while product strategy was reevaluated because sales were minimal.
Its lead allogeneic Olastrocel/AlloStem program is in early clinical studies for chronic lower-back pain associated with degenerative disc disease and recent-onset diabetes. U.S. trial activity is concentrated at individual Florida sites. Earlier programs include ImmCelz, iPScelz, the cell-free Ultrasome knee-osteoarthritis effort, and a veterans exposure-data initiative.
Execution depends on clinical development, FDA authorization and approval, manufacturing, capital, CROs and other partners. Commercial procedures rely on management's stated view that same-surgical-procedure autologous use is exempt from FDA premarket review; future therapeutic sales require approval and either a commercial build-out or partners.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.7M · Total debt $0 · Total assets $9.4M · Shareholders' equity $8.7M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$1.5M
No dividends on record.
| Insiders | 0.01% | 351 shares | |
|---|---|---|---|
| 1 holder · as of Feb 20, 2025 | |||
| Other | 99.99% | 2.58M shares | |
| remainder | |||
2.58M company shares as of Aug 27, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Michael H. FingerInsiderdirector | 0.01% | 351 | filed Feb 20, 2025 |
Altium Capital Management, LPInstitution | —4.99% of class, as filed | — | filed Feb 14, 2022 |
Growth GP, LLCStrategic | —5.70% of class, as filed | — | filed Dec 20, 2021 |
Heights Capital Management, Inc.Strategic | —5.20% of class, as filed | — | filed Dec 10, 2021 |
John MarkeyInsider | —5.10% of class, as filed | — | filed May 2, 2023 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Mesoblast (ADR)
Later-stage allogeneic cells target discogenic chronic low-back pain.
- Vertex Pharmaceuticals
Islet-cell replacement targets the same Type 1 diabetes treatment field.
- BioRestorative Therapies
Cell therapies pursue the same discogenic chronic low-back-pain patients.
- Sana Biotechnology
Hypoimmune islet cells target the same Type 1 diabetes treatment field.
- Viatris
Viagra is a pharmacologic first-line alternative for erectile dysfunction.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Creative Medical Technology | $0.9406 | −6.41% | $2.6M | — | — | 864.5 | 0.0% |
| Mesoblast (ADR) | $15.97 | +3.17% | $2.01B | — | — | 16.6 | +391.8% |
| Vertex Pharmaceuticals | $518.50 | +1.52% | $129.62B | 29.7 | 27.0 | 10.3 | +12.5% |
| BioRestorative Therapies | $2.81 | +3.51% | $3.7M | — | — | 10.5 | −7.3% |
| Sana Biotechnology | $3.30 | +6.29% | $862.7M | — | — | — | — |
| Viatris | $17.19 | +0.51% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Median | 29.7 | 16.9 | 10.4 | +8.7% |